0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TSVT Giù?
Forum
Previsione
Precedente Chiudi:
$5.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$266.14M
Reddito:
$44.12M
Utile/perdita netta:
$-156.25M
Rapporto P/E:
0.00
EPS:
-3.07
Flusso di cassa netto:
$-154.61M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
2 Seventy Bio Inc Stock (TSVT) Company Profile
Nome
2 Seventy Bio Inc
Settore
Industria
Telefono
339-499-9300
Indirizzo
60 BINNEY STREET, CAMBRIDGE
Confronta TSVT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TSVT
2 Seventy Bio Inc
|
0.00 | 266.14M | 44.12M | -156.25M | -154.61M | -3.07 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
375.63 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
559.80 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
435.10 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
672.35 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
298.29 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
2 Seventy Bio Inc Stock (TSVT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-06-06 | Downgrade | Goldman | Neutral → Sell |
2024-01-31 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
2024-01-31 | Downgrade | TD Cowen | Outperform → Market Perform |
2023-10-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
2023-10-12 | Iniziato | Citigroup | Buy |
2023-09-13 | Downgrade | Goldman | Buy → Neutral |
2023-09-12 | Downgrade | Guggenheim | Buy → Neutral |
2023-07-28 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-10-31 | Iniziato | Guggenheim | Buy |
2022-05-02 | Iniziato | Goldman | Buy |
2022-02-10 | Iniziato | SVB Leerink | Outperform |
2022-01-06 | Iniziato | Cowen | Outperform |
2021-11-09 | Iniziato | Canaccord Genuity | Buy |
2021-11-08 | Iniziato | Morgan Stanley | Overweight |
2021-11-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
2 Seventy Bio Inc Borsa (TSVT) Ultime notizie
How 2seventy bio Inc. stock performs during market volatilityControlled Entry Strategy With Safety Analytics - Newser
Long term hold vs stop loss in 2seventy bio Inc.Free Safe Entry Stock Watch Suggestions - Newser
Analyzing net buyer seller activity in 2seventy bio Inc.Swing Gain Strategy with Entry Forecast - Newser
Momentum divergence signals in 2seventy bio Inc. chartFree Weekly Hot Picks With Buy Confidence - Newser
Live Scanner Shows Breakout on 2seventy bio Inc.Watchlist for Smart Swing Trading Updated - metal.it
What drives 2seventy bio Inc. stock priceAchieve rapid portfolio growth with expert guidance - Jammu Links News
How does 2seventy bio Inc. compare to its industry peersFree Stock Market Forecast Reports - Jammu Links News
2seventy bio Inc. Stock Analysis and ForecastConsistent double returns - Jammu Links News
What are the technical indicators suggesting about 2seventy bio Inc.Achieve rapid financial growth with expert help - Jammu Links News
What are analysts’ price targets for 2seventy bio Inc. in the next 12 monthsDiscover breakthrough trading strategies - Jammu Links News
How many analysts rate 2seventy bio Inc. as a “Buy”Explosive portfolio gains - Jammu Links News
Should I hold or sell 2seventy bio Inc. stock in 2025Superior trading gains - Jammu Links News
How does 2seventy bio Inc. generate profit in a changing economyCapitalize on market momentum for maximum gains - Jammu Links News
What is the dividend policy of 2seventy bio Inc. stockCapitalize on fast-growing investment opportunities - Jammu Links News
What makes 2seventy bio Inc. stock price move sharplyConsistently superior profits - Jammu Links News
Is 2seventy bio Inc. stock overvalued or undervaluedHigh-profit stock alerts - Jammu Links News
Why is 2seventy bio Inc. stock attracting strong analyst attentionUnbelievable profit margins - Jammu Links News
What are the latest earnings results for 2seventy bio Inc.Get expert insights on market-moving stocks - Jammu Links News
When is 2seventy bio Inc. stock expected to show significant growthSpectacular growth rates - Jammu Links News
Is 2seventy bio Inc. Stock a Good Fit for Conservative InvestorsBuy Alerts With Low Risk Confirmation Noted - metal.it
Is 2seventy bio Inc. forming a reversal patternTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Momentum Screeners Rank 2seventy bio Inc. in Top 5 TodayAlpha Driven Watchlist With Alerts Published - metal.it
Heatmap Data Shows High Activity in 2seventy bio Inc. SectorReal Time Alerts Based on AI Prediction Triggered - metal.it
Sector Leaders Rotate Capital Into 2seventy bio Inc.Breakout Confirmation With Entry Tracker Enabled - metal.it
2seventy bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayAI Powered Stock Call - metal.it
What catalysts could drive 2seventy bio Inc. stock higher in 2025Track emerging stocks with high growth potential - Jammu Links News
How strong is 2seventy bio Inc. company’s balance sheetAchieve consistent double-digit growth - Jammu Links News
Published on: 2025-07-27 15:37:28 - Jammu Links News
Can 2seventy bio Inc. stock recover from recent declineExplosive earning power - Jammu Links News
Why 2seventy bio Inc. stock attracts strong analyst attentionTop Performing Stocks - beatles.ru
Is 2seventy bio Inc. a good long term investmentDynamic investment growth - Jammu Links News
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades - Managed Healthcare Executive
Cigna Launches AI Tools to Simplify Health Insurance, Improve Customer Experience - Managed Healthcare Executive
FDA Approves Ibtrozi For Adults With ROS1+ NSCLC - Managed Healthcare Executive
Alachua bio-manufacturing plant to lay off employees ahead of shutdown - WCJB | TV20
'Life is too short to work on things that are mediocre': Why this biotech CEO's 2nd drug approval is a big deal - The Business Journals
Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC - Pharmacy Times
Bonnie Hui-Callahan, Pharm.D., Video Interview | 2025 MHE Emerging Leaders in Healthcare - Managed Healthcare Executive
Wellington Management Group LLP Reduces Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
BNP Paribas Financial Markets Makes New Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
Deutsche Bank AG Has $1.10 Million Stock Position in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
MHE Week in Review –Medicaid Bill Mayhem, UnitedHealth’s Stock Plummets and More - Managed Healthcare Executive
Raymond James Financial Inc. Makes New $52,000 Investment in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2Seventy Bio Reports Strong Q1 2025 Earnings - TipRanks
Investor relations - Bristol Myers Squibb
Wells Fargo & Company MN Has $96,000 Stake in 2seventy bio, Inc. (NASDAQ:TSVT) - Defense World
2seventy bio Completes Merger, Delists from Nasdaq - TipRanks
Earnings call transcript: Nuvation Bio Q1 2025 sees strategic focus amid EPS miss - Investing.com India
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb - Business Wire
Stelara Biosimilar Yesintek Gains Coverage on Leading Formularies - Managed Healthcare Executive
2 Seventy Bio Inc Azioni (TSVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):